Abstract
We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 249-251 |
| Number of pages | 3 |
| Journal | Psychopharmacology Bulletin |
| Volume | 33 |
| Issue number | 2 |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
Keywords
- Breastfeeding
- Newborn
- Nortriptyline
- Nortriptyline 10- hydroxymetabolites
- Toxicity monitoring
ASJC Scopus subject areas
- Pharmacology
- Psychiatry and Mental health
Cite this
Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. / Wisner, Katherine L.; Perel, James M.; Findling, Robert L; Hinnes, Robert L.
In: Psychopharmacology Bulletin, Vol. 33, No. 2, 1997, p. 249-251.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns
AU - Wisner, Katherine L.
AU - Perel, James M.
AU - Findling, Robert L
AU - Hinnes, Robert L.
PY - 1997
Y1 - 1997
N2 - We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.
AB - We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.
KW - Breastfeeding
KW - Newborn
KW - Nortriptyline
KW - Nortriptyline 10- hydroxymetabolites
KW - Toxicity monitoring
UR - http://www.scopus.com/inward/record.url?scp=0030795509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030795509&partnerID=8YFLogxK
M3 - Article
C2 - 9230638
AN - SCOPUS:0030795509
VL - 33
SP - 249
EP - 251
JO - Psychopharmacology Bulletin
JF - Psychopharmacology Bulletin
SN - 0048-5764
IS - 2
ER -